How Could Cannabinoids Be Effective in Multiple Evanescent White Dot Syndrome? A Hypothesis

Authors

Amir Hossein Norooznezhad1, 2,*, Fatemeh Norooznezhad1
1Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Tehran, Iran
2Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
*Corresponding Author: Corresponding author: Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. Email:[email protected]

Journal of Reports in Pharmaceutical Sciences:Vol. 5, issue 1; 41-44
Published online:May 23, 2016
Article type:Rapid Communication
Received:Mar 25, 2016
Accepted:May 20, 2016
How to Cite:Norooznezhad AH, Norooznezhad F. How Could Cannabinoids Be Effective in Multiple Evanescent White Dot Syndrome? A Hypothesis. J Rep Pharm Sci. 2016;5(1):e147668. doi:

Abstract

Multiple evanescent white dot syndrome (MEWDS) is an inflammatory eye disease which causes decreasing in visual acuity even to 20/400. So far, no molecular pathway has been suggested for MEWDS. Although no exact treatment is suggested for MEWDS, two major medications are being used for treatment already; anti-vascular endothelial growth factor (VEGF) monoclonal anti-bodies and methylprednisolone. Cannabinoids are known as active compounds of Cannabina Sativa with wide variety of biological activities. Methylprednisolone is able to inhibit inflammation through suppressing Interleukin-6 (IL-6), IL-8, and tumor necrosis factor-α (TNF-α). According to the data, cannabinoids are able to inhibit both angiogenesis and inflammation by targeting VEGF, IL-6, IL-8 and TNF-α and other related angiogenic and inflammatory cytokines. Thus herein authors of this study suggest cannabinoids for treatment of MEWDS since it covers both inhibition of angiogenesis and inflammation. However, feature complementary studies are necessary in the field.

Copyright

© 2016, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

8
Mar
2016

Herpes Zoster, Unusual Skin Presentation as Part of Wegener’s Granulomatosis: A Case Report

Abbas Rasi,
Abbas Zamanian,
Nasrin Shayanfar,
Elham Behrangi,
Zahra Azizian

Rasi A, Zamanian A, Shayanfar N, Behrangi E, Azizian Z. Herpes Zoster, Unusual Skin Presentation as Part of Wegener’s Granulomatosis: A Case Report. Thrita J Neu. 2016;5(2):e59668. doi: https://doi.org/10.5812/thritaj.25757

19
Mar
2011

Angiogenesis and tumor

Kamran Mansouri,
Ali Mostafaie,
Hamid-Reza Mohammadi-Motlagh

Mansouri K, Mostafaie A, Mohammadi-Motlagh H. Angiogenesis and tumor. J Kermanshah Univ Med Sci. 2011;14(4):e79444. doi:

8
Feb
2023
Branch Retinal Vein Occlusion Occurring After Second Dose of Sinopharm COVID-19 Vaccine: A Case Report

Branch Retinal Vein Occlusion Occurring After Second Dose of Sinopharm COVID-19 Vaccine: A Case Report

Leyla Rezaei

Rezaei L. Branch Retinal Vein Occlusion Occurring After Second Dose of Sinopharm COVID-19 Vaccine: A Case Report. J Kermanshah Univ Med Sci. 2022;26(4):e129793. doi: https://doi.org/10.5812/jkums-129793

28
Aug
2016

Cannabinoids as Treatment for Hemophilic Arthropathy: Hypothesized Molecular Pathways

Amir Hossein Norooznezhad,
Fatemeh Norooznezhad,
Nima Bagheri

Norooznezhad AH, Norooznezhad F, Bagheri N. Cannabinoids as Treatment for Hemophilic Arthropathy: Hypothesized Molecular Pathways. J Rep Pharm Sci. 2016;5(2):e147653. doi:

28
Oct
2012

Comparing the Effect of Interavitreal Bevacizumab in Visual Acuity of Ischemic and Non-Ischemic Diabetic Macular Edema

Farzaneh Ghasemzadeh,
Reza Jafari

Ghasemzadeh F, Jafari R. Comparing the Effect of Interavitreal Bevacizumab in Visual Acuity of Ischemic and Non-Ischemic Diabetic Macular Edema. Zahedan J Res Med Sci. 2013;15(2):e93089. doi:

More by these authors

Amir Hossein NorooznezhadPubMedScholar
Fatemeh NorooznezhadPubMedScholar
Share
Cited by
Metrics